Juno Bio, a UK-founded women’s health company dedicated to closing the gender health gap through precision vaginal microbiome testing and multi-omics, today announced the opening of its first sequencing lab built entirely for women’s health.
The new facility, in Oakland, California, marks a major step forward in expanding access to high-quality, clinically relevant microbiome testing.
To fuel this stage of growth, Juno Bio has raised $3.8 million in funding. Investors include Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator, investors known for backing early-stage startups spanning women’s health, deep tech and applied sequencing.
Using next-generation sequencing, Juno Bio’s platform delivers a detailed, clinically actionable view of vaginal health, equipping patients and healthcare providers with deeper insights into conditions that are often misunderstood or misdiagnosed.
Since its founding, Juno Bio has pioneered a new standard of care for vaginal microbiome health, building one of the largest repositories of vaginal microbiome data and helping thousands of women access more precise testing and treatment. Juno Bio’s new clinically actionable vaginal microbiome and STI test is designed to address a critical gap in women’s health, where recurrent infections, fertility concerns, and peri- and menopausal symptoms are frequently misunderstood or inadequately treated.
